College of Pharmacy Dean Receives National Award
CINCINNATI - Daniel Acosta, PhD, dean for the University of Cincinnati College of Pharmacy, will receive the 2006 Award in Excellence of Pharmacology/Toxicology from the Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation. The presentation will be made at the groups annual meeting April 1 in
The award is given annually to honorees who received a grant from PhRMA at the onset of their career and have gone on to distinguish themselves in research or administration.
I received my first grant from PhRMA at a critical point in my scientific career, says Dr. Acosta, a
He began his career as a research assistant at the
In 1996, Dr. Acosta became dean of UCs
Dr. Acostas own research has focused on the development of in vitro cell cultures as models for testing and mechanistic studies on drugs and toxicants. He was a key researcher in culturing cells that mimicked the normal tissues from which they were derived, which greatly reduced the need for experimental animal testing. The Society of Toxicology, the largest toxicology organization in the world, honored him for this work with the 2005 Enhancement of Animal Welfare Award.
In addition to being a pioneer in the development of alternative in vitro test methods, Dr. Acosta was successful in maintaining viable cultured cells from multiple sites, including liver, heart, kidney and nervous tissues.
Dr. Acosta has published over 125 original papers in peer-reviewed journals, authored 28 book chapters or reviews and edited three books.
Dr. Acosta is an inspirational leader to the faculty and students in the
Active in numerous scientific, professional and government organizations, Dr. Acosta is currently chairman of the FDA Scientific Advisory Board for the
Receiving this award is deeply humbling, says Dr. Acosta, especially since as an active administrator Im no longer directly involved in research. Im honored that the PhRMA believes my career can be considered one of excellence.
Tags
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.
Heavy social media use linked to depression
August 31, 2026
U.S. News and World Report, Yahoo! News, MSN, USA Today and other national media highlight a new study by the University of Cincinnati and Northwestern University that found a correlation between heavy social media use and depression in adults.